Congratulations to Dr. George Wandling, who was chosen as an investigator for the Ivantis Hydrus FDA clinical trial. Dr. Wandling’s selection makes North Metro Surgery Center one of only 15 sites across the United States active in this prospective, post-approval FDA study, designed to determine the ongoing safety of the device. It will soon be wrapping up its 24-month study results.
The Hydrus is a MIGS (Microinvasive Glaucoma Surgery) device implanted at the time of cataract surgery and is used to treat mild to moderate open angle glaucoma.
Dr. Wandling is a leading expert on cataract and cataract/MIGS surgery and we’re proud of his accomplishments, research, and contributions to the field of ocular surgery.